Reata Pharmaceuticals (RETA) Reports Q2 Loss of $0.05/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts RETA Hot Sheet
Join SI Premium – FREE
Reata Pharmaceuticals (NASDAQ: RETA) reported Q2 EPS of ($0.05), versus ($0.11) reported last year. Revenue for the quarter came in at $12.4 million, versus $12.4 million reported last year.
For earnings history and earnings-related data on Reata Pharmaceuticals (RETA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ONEOK (OKE) Tops Q3 EPS by 63c; raises guidance
- Christopher & Banks (CBK) Tops Q3 EPS by 79c
- Home Federal Bancorp of Louisiana (HFBL) Tops Q3 EPS by 64c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
